Article Text

other Versions

PDF
Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of phenylalanine-restricted diet
  1. Philip J Lee (philip.lee{at}uclh.org)
  1. National Hospital for Neurology & Neurosurgery, London, United Kingdom
    1. Allayne Amos
    1. The Tizard Centre, University of Kent, United Kingdom
      1. Lesley Robertson
      1. National Hospital for Neurology & Neurosurgery, London, United Kingdom
        1. Brian Fitzgerald
        1. Enfield PCT, United Kingdom
          1. Rosemary Hoskin
          1. NW Herts NHS Trust, United Kingdom
            1. Maggie Lilburn
            1. National Hospital for Neurology & Neurosurgery, London, United Kingdom
              1. Eleanor Weetch
              1. NSPKU, United Kingdom
                1. Glynis Murphy (g.h.murphy{at}kent.ac.uk)
                1. The Tizard Centre, University of Kent, United Kingdom

                  Abstract

                  Background: Although early diagnosis and treatment in phenylketonuria (PKU) leads to excellent outcomes, a population of adults born before the introduction of newborn screening exists. They can have severe intellectual disabilities and behavioural problems and are often dependent on full-time carers. Anecdotal evidence suggests that a diet that lowers blood phenylalanine concentration can have significant benefits upon behaviour.

                  Methods: A prospective double-blind randomised placebo-controlled crossover trial of phenylalanine-restricted diet was performed in a group of 34 adults (aged 21-61 years, median 49) with late diagnosed PKU with severe challenging behaviour.

                  Results: Only 17 completed the 60 week study: 7 withdrew before the end of the baseline period; 5 withdrew during the first diet period; 5 withdrew during the second diet period (after moving into placebo phase). Mean (± SD) blood phenylalanine was 1570 (± 222)μmol/l during baseline, 553(± 158) μmol/l during the active phase and 1444 (± 255) μmol/l during the placebo phase. In the 22 participants exposed to both active and placebo phases, no differences were demonstrated in behaviour assessed by the Aberrant Behaviour Checklist and Vineland Adaptive Behaviour Scales, behaviour diaries or on video analysis of direct observations. However, 76% of carers' comments were scored as positive during the active phase, compared to 54% during the placebo phase (Chi-square=38.06, p<0.001).

                  Conclusions: There are significant challenges in studying people with intellectual disabilities and considerable difficulties in instituting phenylalanine-restricted diet in this population. However, if attempted, there are potential benefits to quality of life for the individuals with PKU and their carers.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                  Linked Articles

                  • Editorial commentary
                    Francjan van Spronsen
                  • Editorial commentary
                    Christopher Kennard